Genital Herpes (HSV-2 / HSV-1 Genital) Treatment
Covered by Aetna in California

FIRST EPISODE: valacyclovir 1g orally twice daily × 7–10 days OR acyclovir 400mg orally three times daily × 7–10 days — per CDC STI Treatment Guidelines (current 2024). Treatment can be extended if healing is incomplete at 10 days. SUPPRESSIVE THERAPY (recurrent outbreaks, ≥6/year, or transmission reduction): valacyclovir 500mg orally once daily (may reduce to 1g daily for ≥10 outbreaks/year) OR acyclovir 400mg orally twice daily. EPISODIC THERAPY (self-initiation at first sign of outbreak): valacyclovir 500mg orally twice daily × 3 days OR valacyclovir 1g once daily × 5 days OR acyclovir 800mg orally twice daily × 5 days

Famciclovir 250mg orally three times daily × 7–10 days (first episode); famciclovir 125mg twice daily × 5 days or 1g twice daily × 1 day (episodic recurrences); famciclovir 250mg twice daily (suppressive). Acyclovir and valacyclovir are preferred for suppressive therapy given cost advantage. For HIV-coinfected patients: acyclovir 400–800mg orally 2–3 times daily for suppression per CDC HIV guidelines.

Yes — generic valacyclovir 500mg and 1g tablets are Tier 1 on Aetna CA with no prior authorization. Cost: typically $10–$25 for a 30-tablet supply (30 days suppression or episodic supply). Generic acyclovir 400mg tablets are also Tier 1, typically $4–$10. Famciclovir generic is Tier 1. 90-day supply fills available for suppressive therapy patients, reducing pharmacy trips.

Suppressive antiviral therapy reduces HSV-2 transmission risk to susceptible partners by approximately 50% (valacyclovir 500mg daily, Corey et al., NEJM 2004), in combination with consistent condom use. Annual reassessment of suppressive therapy is recommended by CDC as outbreak frequency naturally decreases over time for many patients. Neonatal herpes risk from HSV-2 in pregnant women warrants suppressive acyclovir 400mg TID or valacyclovir 500mg BID from 36 weeks gestation through delivery — requires OB coordination. First-episode suspected HSV with severe systemic symptoms (fever, aseptic meningitis, disseminated infection) requires in-person ER evaluation.

The choice depends on three factors: outbreak frequency, transmission concern, and patient preference. Daily suppressive therapy (valacyclovir 500mg once daily) is recommended by CDC when you have 6 or more outbreaks per year, have an HSV-negative partner you want to protect, or find managing episodic outbreaks disruptive to daily life. Suppressive therapy reduces outbreak frequency by 70–80%, reduces asymptomatic viral shedding, and reduces transmission risk by approximately 50%. Episodic therapy (taking a short course at the first sign of an outbreak) is appropriate when outbreaks are infrequent (< 6/year), you have no current serodiscordant partner, and you prefer to avoid daily medication. Dr. Bhavsar discusses both approaches at the visit.

Yes. Generic valacyclovir 500mg or 1g tablets and generic acyclovir 400mg tablets are Tier 1 on Aetna CA with no prior authorization and no time limit on the prescription. Suppressive therapy can be prescribed as a 90-day maintenance supply and refilled indefinitely. The annual cost for daily valacyclovir 500mg is typically $60–$120 with Aetna CA Tier 1 copays — often comparable to a one-month supply of branded Valtrex without insurance. GoodRx often brings generic valacyclovir below $15/month at California pharmacies.

California's expedited partner therapy (EPT) law covers chlamydia, gonorrhea, and trichomoniasis — it does not extend to herpes or other viral infections. A partner who had a significant HSV exposure should have their own clinical evaluation. At a TDMD visit, Dr. Bhavsar can counsel you on transmission risk, discuss whether your partner should start suppressive therapy themselves, and provide documentation supporting your partner's own insurance-covered visit. There is no FDA-approved post-exposure prophylaxis regimen for HSV after a specific exposure.

Antiviral resistance to acyclovir and valacyclovir is rare in immunocompetent patients on long-term suppressive therapy — studies show resistance rates below 0.5% in this population. Resistance is more clinically relevant in immunocompromised patients (HIV with low CD4 counts, transplant recipients) who may need foscarnet or cidofovir as alternatives. For healthy individuals on suppressive valacyclovir, resistance is not a reason to avoid long-term therapy. Annual reassessment of ongoing need is recommended, as outbreak frequency naturally decreases over time for many patients.

Yes. Aetna commercial plans cover telehealth visits for Genital Herpes (HSV-2 / HSV-1 Genital) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your genital herpes treatment visit. Self-pay is always available for a flat $79 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $79 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your genital herpes treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $79 self-pay option is also FSA/HSA eligible.